Listed

Nuo Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2017

Filed with the SEC on Nov 13, 2017 and accepted by EDGAR at Nov 13, 2017, 17:17 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2017-07-01 to 2017-09-30$162.2kus-gaap:Revenues
Revenue9 months2017-01-01 to 2017-09-30$523.5kus-gaap:Revenues
Cost of revenue3 months2017-07-01 to 2017-09-30$264.0kus-gaap:CostOfRevenue
Cost of revenue9 months2017-01-01 to 2017-09-30$811.5kus-gaap:CostOfRevenue
Gross profit3 months2017-07-01 to 2017-09-30−$101.8kus-gaap:GrossProfit
Gross profit9 months2017-01-01 to 2017-09-30−$287.9kus-gaap:GrossProfit
Research and development3 months2017-07-01 to 2017-09-30$299.5kus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2017-01-01 to 2017-09-30$1.0mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2017-07-01 to 2017-09-30−$1.4mus-gaap:OperatingIncomeLoss
Operating income9 months2017-01-01 to 2017-09-30−$7.0mus-gaap:OperatingIncomeLoss
Net income3 months2017-07-01 to 2017-09-30−$1.4mus-gaap:NetIncomeLoss
Net income9 months2017-01-01 to 2017-09-30−$7.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2017-07-01 to 2017-09-30−$0.09us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2017-01-01 to 2017-09-30−$0.59us-gaap:EarningsPerShareDiluted
Basic EPS3 months2017-07-01 to 2017-09-30−$0.09us-gaap:EarningsPerShareBasic
Basic EPS9 months2017-01-01 to 2017-09-30−$0.59us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2017-07-01 to 2017-09-3015,852,764 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2017-01-01 to 2017-09-3011,924,035 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2017-01-01 to 2017-09-30−$3.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2017-09-30$1.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2017-09-30$2.6mus-gaap:AssetsCurrent
Total assetsAt period end2017-09-30$10.2mus-gaap:Assets
Current liabilitiesAt period end2017-09-30$1.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-09-30$1.7mus-gaap:Liabilities
Shareholders' equityAt period end2017-09-30$8.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001437749-17-019152. Last ingested by Listed: Nov 14, 2026, 23:44 ET. Listed shows no prices and gives no investment advice.